Vistin Pharma ASALTS:0RAM 77 Days Payable is 64.47 as of Mar. 2026, which is 9% above its 10-year median of 58.90. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 72.56% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Days Payable or its related term are showing as below:
LTS:0RAM'
s Days Payable Range Over the Past 10 Years
Min: 27.22 Med: 58.9 Max: 162.1
Current: 53.56
During the past 13 years, Vistin Pharma ASA's highest Days Payable was 162.10. The lowest was 27.22. And the median was 58.90.
LTS:0RAM's Days Payable is ranked worse than 72.56% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs LTS:0RAM: 53.56
Vistin Pharma ASA's Days Payable
increased
from Mar. 2025 (35.48) to Mar. 2026 (64.47).
It may suggest that Vistin Pharma ASAdelayed paying its suppliers.
Vistin Pharma ASA Days Payable Related Terms
Vistin Pharma ASA Days Payable Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Days Payable distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vistin Pharma ASA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a Days Payable of 64.47 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vistin Pharma ASA and its competitors. This is near median its historical median of 58.90. Over the past decade, Vistin Pharma ASA's Days Payable has ranged from 27.22 to 162.10. According to the industry distribution chart, Vistin Pharma ASA ranks #669 out of 922 companies in the Drug Manufacturers industry, placing it in the top 72.6%.
Is Vistin Pharma ASA's Days Payable too high?
Vistin Pharma ASA's current Days Payable of 64.47 is near median its 10-year median of 58.90. Over the past 10 years, this metric has ranged from a low of 27.22 to a high of 162.10. The Drug Manufacturers industry median Days Payable is 90.61. Vistin Pharma ASA's value of 64.47 is 28.8% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #669 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #669 out of 922 companies for Days Payable. This places Vistin Pharma ASA in the lower half of its industry. The industry median Days Payable is 90.61. Vistin Pharma ASA's value of 64.47 is 28.8% below this benchmark. Historically, Vistin Pharma ASA's own Days Payable has ranged from 27.22 to 162.10 over the past decade. While the company's 10-year median is 58.90 vs. the industry median of 90.61, Vistin Pharma ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Days Payable of 64.47 is 28.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Days Payable is 64.47, which is near median its own 10-year median of 58.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Days Payable is 64.47, which is near median its 10-year median of 58.90 and 28.8% below the Drug Manufacturers industry median of 90.61. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Days Payable is 64.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Days Payable: 64.47 (near median its 10-year median of 58.90)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 28.8% below the Drug Manufacturers median (#669 of 922)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
